License Agreement, Minimum Ownership Threshold, Percent

No definition available.

Name:	allo_LicenseAgreementMinimumOwnershipThresholdPercent
Namespace Prefix:	allo_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Remaining Performance Obligations Extinguished

+ References

No definition available.

+ Details

Name:	allo_NumberOfRemainingPerformanceObligationsExtinguished
Namespace Prefix:	allo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue, Remaining Performance Obligation, Extinguished, Amount

+ References

No definition available.

+ Details

Name:	allo_RevenueRemainingPerformanceObligationExtinguishedAmount
Namespace Prefix:	allo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount

+ References

No definition available.

+ Details

Name:	allo_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix:	allo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Shareholders’ Agreement, Protective Shareholder Right Retained, Share Transfer Threshold, Percentage

+ References

No definition available.

+ Details

Name:	allo_ShareholdersAgreementProtectiveShareholderRightRetainedShareTransferThresholdPercentage
Namespace Prefix:	allo_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Shares Surrendered Under Termination Of License Agreement

+ References

No definition available.

+ Details

Name:	allo_SharesSurrenderedUnderTerminationOfLicenseAgreement
Namespace Prefix:	allo_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481664/323-10-45-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_EquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.

+ References

No definition available.

+ Details

Name:	us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The parent entity's interest in net assets of the subsidiary, expressed as a percentage.

+ References

No definition available.

+ Details

Name:	us-gaap_MinorityInterestOwnershipPercentageByParent
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=allo_OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=allo_ManufacturingLicenseKnowHowMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=allo_KnowHowDevelopedInFuturePeriodsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=allo_OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=allo_OverlandPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=allo_OverlandUSMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	allo_EquityInvestmentBasisAxis=allo_VotingInterestMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreements - Overland Therapeutics, Inc. (Details)		3 Months Ended		6 Months Ended
	May 12, 2026 USD ($) performanceObligation shares	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	May 11, 2026	Dec. 31, 2025 USD ($)	May 24, 2024 USD ($)	Dec. 14, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of remaining performance obligations extinguished \| performanceObligation	2
Collaboration revenue - related party		$ 4,640,000	$ 0	$ 4,640,000	$ 0
Overland Therapeutics (Formerly Known As Allogene Overland)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Shares surrendered in connection with termination of license agreement (in shares) \| shares	40,353,951
Overland Therapeutics (Formerly Known As Allogene Overland) \| License \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue, remaining performance obligation, variable consideration amount								$ 115,000,000.0
Overland Therapeutics (Formerly Known As Allogene Overland) \| Manufacturing License, Know-How
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Remaining performance obligation, extinguished	$ 1,900,000
Overland Therapeutics (Formerly Known As Allogene Overland) \| Know-How Developed In Future Periods
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Remaining performance obligation, extinguished	$ 2,700,000
Overland Therapeutics (Formerly Known As Allogene Overland)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Subsidiary, ownership percentage, noncontrolling owner								18.00%
License agreement, minimum ownership threshold, percent								0.075
Overland Pharmaceuticals Inc. \| Overland Therapeutics (Formerly Known As Allogene Overland)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Subsidiary, ownership percentage, parent								82.00%
Overland Pharmaceuticals Inc. \| Overland US
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Subsidiary, ownership percentage, parent								100.00%
Overland Therapeutics (Formerly Known As Allogene Overland)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Ownership percentage	3.00%								49.00%
Equity method investments		0		0			$ 0
Share transfer to non affiliate, percentage	25.00%
Collaboration revenue - related party		$ 4,600,000	$ 0	$ 4,600,000	$ 0
Overland Therapeutics (Formerly Known As Allogene Overland) \| Voting Interest
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Ownership percentage		20.00%		20.00%		20.00%
Overland Therapeutics (Formerly Known As Allogene Overland) \| Overland Pharmaceuticals Inc.
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Ownership percentage									51.00%